Critical Survey: SOPHiA GENETICS (SOPH) versus Its Rivals

SOPHiA GENETICS (NASDAQ:SOPH – Get Free Report) is one of 93 publicly-traded companies in the “Healthcare Technology” industry, but how does it weigh in compared to its peers? We will compare SOPHiA GENETICS to related companies based on the strength of its analyst recommendations, dividends, valuation, institutional ownership, risk, profitability and earnings.

Insider & Institutional Ownership

31.6% of SOPHiA GENETICS shares are owned by institutional investors. Comparatively, 42.4% of shares of all “Healthcare Technology” companies are owned by institutional investors. 4.9% of SOPHiA GENETICS shares are owned by insiders. Comparatively, 16.2% of shares of all “Healthcare Technology” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current recommendations for SOPHiA GENETICS and its peers, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SOPHiA GENETICS 1 1 3 0 2.40
SOPHiA GENETICS Competitors 456 1541 2763 89 2.51

SOPHiA GENETICS currently has a consensus target price of $10.00, suggesting a potential upside of 58.20%. As a group, “Healthcare Technology” companies have a potential upside of 54.39%. Given SOPHiA GENETICS’s higher possible upside, equities analysts clearly believe SOPHiA GENETICS is more favorable than its peers.

Volatility and Risk

SOPHiA GENETICS has a beta of 1.09, suggesting that its stock price is 9% more volatile than the S&P 500. Comparatively, SOPHiA GENETICS’s peers have a beta of 1.11, suggesting that their average stock price is 11% more volatile than the S&P 500.

Valuation and Earnings

This table compares SOPHiA GENETICS and its peers revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
SOPHiA GENETICS $77.27 million -$79.00 million -5.80
SOPHiA GENETICS Competitors $341.86 million -$24.15 million 11.43

SOPHiA GENETICS’s peers have higher revenue and earnings than SOPHiA GENETICS. SOPHiA GENETICS is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares SOPHiA GENETICS and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
SOPHiA GENETICS -89.18% -128.69% -44.73%
SOPHiA GENETICS Competitors -749.77% -27.84% -15.02%

Summary

SOPHiA GENETICS peers beat SOPHiA GENETICS on 10 of the 13 factors compared.

About SOPHiA GENETICS

(Get Free Report)

SOPHiA GENETICS is a healthcare technology company that develops data-analysis tools for genomics and other complex health data. Its cloud-based SOPHiA DDM platform uses artificial intelligence and analytics to help healthcare and research organizations interpret data and support clinical and scientific decision-making. The platform and related applications are used in areas including oncology, rare diseases and inherited conditions. The company serves hospitals, laboratories, biopharmaceutical companies and research organizations, with a presence across international markets.

Receive News & Ratings for SOPHiA GENETICS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SOPHiA GENETICS and related companies with MarketBeat.com's FREE daily email newsletter.